Clinical trial · no report yet · Phase 2
CUPISCO
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- NCT03498521 ↗
- Completed
- Hoffmann-La Roche
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 24 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Cancer of Unknown Primary Site
- Interventions
- Alectinib; Vismodegib; Ipatasertib; Olaparib; Erlotinib; Bevacizumab; Vemurafenib; Cobimetinib; Trastuzumab Subcutaneous (SC); Pertuzumab; Atezolizumab; Carboplatin; Paclitaxel; Cisplatin; Gemcitabine; Entrectinib; Ivosidenib; Pemigatinib
- Arms
- Molecularly-Guided Therapy · Experimental
- Platinum-Based Chemotherapy · Active comparator
- Enrollment
- 529
- Primary outcomes
- Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)
- Sponsor
- Hoffmann-La Roche with Foundation Medicine
- Start
- Jul 10, 2018
- Primary completion
- Feb 14, 2023
- Results posted
- Yes
- Registry record
- NCT03498521 · updated Nov 19, 2025
Publications
linked from the registry- Kramer A, Bochtler T, Pauli C, Shiu KK, Cook N, Janoski de Menezes J, Pazo-Cid RA, Losa F, Robbrecht DGJ, Tomasek J, Arslan C, Ozguroglu M, Arni P, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Duran-Pacheco G, Ma N, Scarato J, Ross JS, Moch H, Mileshkin L. Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study. J Clin Oncol. 2026 Sep 3:JCO2502974. doi: 10.1200/JCO-25-02974. Online ahead of print. PubMed 42691436
- Kramer A, Bochtler T, Pauli C, Shiu KK, Cook N, de Menezes JJ, Pazo-Cid RA, Losa F, Robbrecht DG, Tomasek J, Arslan C, Ozguroglu M, Stahl M, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Duran-Pacheco G, Michaud C, Scarato J, Thomas M, Ross JS, Moch H, Mileshkin L. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31. PubMed 39096924